Longpre Lara 4
4 · Mirum Pharmaceuticals, Inc. · Filed May 12, 2022
Insider Transaction Report
Form 4
Longpre Lara
Chief Development Officer
Transactions
- Award
Common Stock
2022-05-10$13.57/sh+1,454$19,725→ 96,452 total
Footnotes (1)
- [F1]This Form 4 is being filed voluntarily to report the acquisition of 1,454 shares by the Reporting Person on May 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.